資本界金控(00204.HK)已與成都冠德堂生物科技就可能成立一間合資公司進行一系列討論
格隆匯10月25日丨資本界金控(00204.HK)發佈公吿,集團一直積極尋求新商機以多元化發展其業務及增強長期增長及股東價值。公司董事會欣然公吿,公司近期已與潛在業務合作伙伴成都冠德堂生物科技集團有限公司就可能成立一間合資公司進行一系列討論,該合作伙伴在生物科技領域擁有豐富的經驗。初階段合資公司的主要目標市場為中國,將來可能進一步拓展至其他國家。
公司認為生物科技市場具有良好的發展前景。成立合資公司符合集團的業務發展策略及計劃,為集團提供擴大其業務範圍至生物科技業務的良機。
董事會認為,成立合資公司如果實現將可能為公司開拓新的收入來源,並最大限度地提高對公司及其股東的長遠回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.